CN106589039A - 一种奥贝胆酸的制备方法及相关化合物 - Google Patents
一种奥贝胆酸的制备方法及相关化合物 Download PDFInfo
- Publication number
- CN106589039A CN106589039A CN201510686399.8A CN201510686399A CN106589039A CN 106589039 A CN106589039 A CN 106589039A CN 201510686399 A CN201510686399 A CN 201510686399A CN 106589039 A CN106589039 A CN 106589039A
- Authority
- CN
- China
- Prior art keywords
- preparation
- reaction
- acid
- follows
- jing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims description 11
- 238000000034 method Methods 0.000 title abstract description 10
- 229960001601 obeticholic acid Drugs 0.000 title abstract description 5
- ZXERDUOLZKYMJM-ZWECCWDJSA-N obeticholic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)CCC(O)=O)CC[C@H]21 ZXERDUOLZKYMJM-ZWECCWDJSA-N 0.000 title abstract description 4
- 239000002253 acid Substances 0.000 claims abstract description 13
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 25
- 238000006243 chemical reaction Methods 0.000 claims description 24
- 235000015170 shellfish Nutrition 0.000 claims description 24
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims description 23
- 239000004380 Cholic acid Substances 0.000 claims description 23
- 229960002471 cholic acid Drugs 0.000 claims description 23
- 235000019416 cholic acid Nutrition 0.000 claims description 23
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 23
- 238000002360 preparation method Methods 0.000 claims description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 15
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 14
- 239000003054 catalyst Substances 0.000 claims description 9
- -1 boron Sodium hydride Chemical compound 0.000 claims description 8
- 238000006722 reduction reaction Methods 0.000 claims description 8
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 230000003197 catalytic effect Effects 0.000 claims description 5
- 239000012279 sodium borohydride Substances 0.000 claims description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- 239000003638 chemical reducing agent Substances 0.000 claims description 4
- 229910052763 palladium Inorganic materials 0.000 claims description 4
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 238000005984 hydrogenation reaction Methods 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 229910019020 PtO2 Inorganic materials 0.000 claims description 2
- JFBZPFYRPYOZCQ-UHFFFAOYSA-N [Li].[Al] Chemical compound [Li].[Al] JFBZPFYRPYOZCQ-UHFFFAOYSA-N 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 claims description 2
- 235000010216 calcium carbonate Nutrition 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 238000006555 catalytic reaction Methods 0.000 claims description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 claims description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 claims description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 150000004880 oxines Chemical class 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 150000004702 methyl esters Chemical class 0.000 abstract description 14
- 239000002994 raw material Substances 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 4
- 239000012535 impurity Substances 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 238000010189 synthetic method Methods 0.000 abstract 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- 239000012074 organic phase Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 150000002576 ketones Chemical group 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 235000011167 hydrochloric acid Nutrition 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- 125000003716 cholic acid group Chemical group 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- 238000007605 air drying Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000005292 vacuum distillation Methods 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- CXDHJGCWMIOAQP-UHFFFAOYSA-N 2-pyridin-3-yl-1,4,5,6-tetrahydropyrimidine;hydrochloride Chemical compound Cl.C1CCNC(C=2C=NC=CC=2)=N1 CXDHJGCWMIOAQP-UHFFFAOYSA-N 0.000 description 1
- FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 description 1
- 102100038495 Bile acid receptor Human genes 0.000 description 1
- 102100038637 Cytochrome P450 7A1 Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 description 1
- 101000957672 Homo sapiens Cytochrome P450 7A1 Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Steroid Compounds (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510686399.8A CN106589039B (zh) | 2015-10-15 | 2015-10-15 | 一种奥贝胆酸的制备方法及相关化合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510686399.8A CN106589039B (zh) | 2015-10-15 | 2015-10-15 | 一种奥贝胆酸的制备方法及相关化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106589039A true CN106589039A (zh) | 2017-04-26 |
CN106589039B CN106589039B (zh) | 2019-12-17 |
Family
ID=58555179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510686399.8A Active CN106589039B (zh) | 2015-10-15 | 2015-10-15 | 一种奥贝胆酸的制备方法及相关化合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106589039B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107400154A (zh) * | 2016-05-18 | 2017-11-28 | 北京凯因科技股份有限公司 | 一种制备3α,7α-二-羟基-6α-乙基-5β-胆烷酸的方法 |
CN107917972A (zh) * | 2017-11-03 | 2018-04-17 | 江苏开元药业有限公司 | 一种高效液相色谱分析奥贝胆酸及其合成中间体的方法 |
CN107955058A (zh) * | 2018-01-08 | 2018-04-24 | 常州制药厂有限公司 | 一种用于制备奥贝胆酸的中间体、其制备方法以及奥贝胆酸的制备 |
ES2724725A1 (es) * | 2018-03-07 | 2019-09-13 | Moehs Iberica Sl | Síntesis de ácido obeticólico e intermedio de síntesis |
WO2020169643A1 (en) | 2019-02-20 | 2020-08-27 | Moehs Iberica, S.L. | DIETHYLAMINE SALT OF 3α-TETRAHYDROPYRANYLOXY-6α-ETHYL-7α-HYDROXY-5ß-CHOLANIC ACID |
CN112898369A (zh) * | 2019-12-04 | 2021-06-04 | 博瑞生物医药(苏州)股份有限公司 | 用于制备奥贝胆酸的方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0312867A1 (en) * | 1987-10-20 | 1989-04-26 | GIULIANI S.p.A. | Billiary acid derivatives, processes for the preparation thereof and phamaceutical compositions containing them |
WO2002072598A1 (en) * | 2001-03-12 | 2002-09-19 | Roberto Pellicciari | Steroids as agonists for fxr |
US20090062526A1 (en) * | 2007-08-28 | 2009-03-05 | Yu Donna D | novel method of synthesizing alkylated bile acid derivatives |
CN104781272A (zh) * | 2012-06-19 | 2015-07-15 | 英特塞普特医药品公司 | 奥贝胆酸的制备、用途和固体形式 |
CN104853758A (zh) * | 2012-11-28 | 2015-08-19 | 英特赛普特医药品公司 | 肺部疾病的治疗 |
CN104876995A (zh) * | 2014-02-27 | 2015-09-02 | 人福医药集团股份公司 | 鹅去氧胆酸衍生物的制备方法 |
CN105669811A (zh) * | 2014-11-17 | 2016-06-15 | 正大天晴药业集团股份有限公司 | 新的7-酮-6β-烷基胆烷酸衍生物在制备奥贝胆酸以及其在医药领域的用途 |
-
2015
- 2015-10-15 CN CN201510686399.8A patent/CN106589039B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0312867A1 (en) * | 1987-10-20 | 1989-04-26 | GIULIANI S.p.A. | Billiary acid derivatives, processes for the preparation thereof and phamaceutical compositions containing them |
WO2002072598A1 (en) * | 2001-03-12 | 2002-09-19 | Roberto Pellicciari | Steroids as agonists for fxr |
US20090062526A1 (en) * | 2007-08-28 | 2009-03-05 | Yu Donna D | novel method of synthesizing alkylated bile acid derivatives |
CN104781272A (zh) * | 2012-06-19 | 2015-07-15 | 英特塞普特医药品公司 | 奥贝胆酸的制备、用途和固体形式 |
CN104853758A (zh) * | 2012-11-28 | 2015-08-19 | 英特赛普特医药品公司 | 肺部疾病的治疗 |
CN104876995A (zh) * | 2014-02-27 | 2015-09-02 | 人福医药集团股份公司 | 鹅去氧胆酸衍生物的制备方法 |
CN105669811A (zh) * | 2014-11-17 | 2016-06-15 | 正大天晴药业集团股份有限公司 | 新的7-酮-6β-烷基胆烷酸衍生物在制备奥贝胆酸以及其在医药领域的用途 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107400154A (zh) * | 2016-05-18 | 2017-11-28 | 北京凯因科技股份有限公司 | 一种制备3α,7α-二-羟基-6α-乙基-5β-胆烷酸的方法 |
CN107917972A (zh) * | 2017-11-03 | 2018-04-17 | 江苏开元药业有限公司 | 一种高效液相色谱分析奥贝胆酸及其合成中间体的方法 |
CN107955058A (zh) * | 2018-01-08 | 2018-04-24 | 常州制药厂有限公司 | 一种用于制备奥贝胆酸的中间体、其制备方法以及奥贝胆酸的制备 |
ES2724725A1 (es) * | 2018-03-07 | 2019-09-13 | Moehs Iberica Sl | Síntesis de ácido obeticólico e intermedio de síntesis |
WO2020169643A1 (en) | 2019-02-20 | 2020-08-27 | Moehs Iberica, S.L. | DIETHYLAMINE SALT OF 3α-TETRAHYDROPYRANYLOXY-6α-ETHYL-7α-HYDROXY-5ß-CHOLANIC ACID |
CN112898369A (zh) * | 2019-12-04 | 2021-06-04 | 博瑞生物医药(苏州)股份有限公司 | 用于制备奥贝胆酸的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN106589039B (zh) | 2019-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106589039A (zh) | 一种奥贝胆酸的制备方法及相关化合物 | |
CN104530166B (zh) | 选择性还原4,6-共轭双烯-3-酮甾体化合物的方法 | |
CN106905388A (zh) | 一种天麻素的合成方法 | |
CN105263945B (zh) | 一种酸催化醛糖或酮糖直接与苷元反应制备皂苷的方法 | |
Xue et al. | A total synthesis of OSW-1 | |
CN106916196A (zh) | 一种奥贝胆酸中间体的合成方法 | |
CN106986909A (zh) | 一种用于治疗肝病药物中间体的合成方法 | |
CN101239917B (zh) | 一种盐酸利托君及其中间体的制备方法 | |
CN103665085B (zh) | 一种改进的乙酸阿比特龙酯合成方法 | |
CN108191925A (zh) | 吉西他滨关键中间体磺化糖的工业制备工艺 | |
CN112538099A (zh) | 一种全酰基保护的1-硫代葡萄糖、葡萄糖1-硫醇的制备方法及其应用 | |
CN103044468A (zh) | N-(2-吡嗪羰基)-l-苯丙氨酸-l-亮氨酸硼酸的制备方法 | |
CN111559995A (zh) | 一种抗坏血酸乙基醚的制备工艺 | |
CN108658733B (zh) | 一种2,4,6-三碘间苯二酚的制备方法 | |
CN102153461A (zh) | 一种由乙二醇制备羟基乙酸的方法 | |
CN106167465B (zh) | 一种依达拉奉二聚体杂质化合物及其制备方法 | |
CN104650160A (zh) | 卡培他滨关键中间体1,2,3-o-三乙酰基-5-脱氧-d-核糖的合成新方法 | |
CN107663221A (zh) | 一种奥贝胆酸的制备方法 | |
CN104372052A (zh) | 一种化学法合并酶法制备糖苷类化合物的方法 | |
CN105218613A (zh) | 一种快速高效水解三七叶总皂苷制备人参皂苷Rg3,Rh2的方法 | |
CN106316802A (zh) | 单分散九聚乙二醇十二烷基醇单醚及其硫酸盐的制备方法和应用 | |
CN107056849B (zh) | 一种全乙酰基保护α-2,6-二脱氧葡萄糖-O-糖苷的制备方法 | |
KR950007250B1 (ko) | 사포닌의 제조방법 | |
CN114644679B (zh) | 葡萄糖醛酸糖苷类化合物、其制备方法及应用 | |
CN109942639B (zh) | 一种高纯度果糖二磷酸镁的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 215123 Suzhou Industrial Park, Suzhou, Jiangsu, No. 388, Nanshui, 7 D, National Science and Technology Park, Nanshui University. Applicant after: SUZHOU LANXITE BIOTECHNOLOGY Co.,Ltd. Address before: 215123 Jiangsu Suzhou Industrial Park, No. 388, No. 7, D building, National Science and Technology Park, National University of Suzhou. Applicant before: SUZHOU LANXITE BIOTECHNOLOGY Co.,Ltd. |
|
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20170426 Assignee: Suzhou ronghua Leasing Co.,Ltd. Assignor: SUZHOU LANXITE BIOTECHNOLOGY Co.,Ltd. Contract record no.: X2020320010026 Denomination of invention: A preparation method and related compounds of oxycholic acid Granted publication date: 20191217 License type: Exclusive License Record date: 20201201 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A preparation method and related compounds of oxycholic acid Effective date of registration: 20201203 Granted publication date: 20191217 Pledgee: Suzhou ronghua Leasing Co.,Ltd. Pledgor: SUZHOU LANXITE BIOTECHNOLOGY Co.,Ltd. Registration number: Y2020320010214 |
|
EC01 | Cancellation of recordation of patent licensing contract | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Suzhou ronghua Leasing Co.,Ltd. Assignor: SUZHOU LANXITE BIOTECHNOLOGY Co.,Ltd. Contract record no.: X2020320010026 Date of cancellation: 20230901 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230901 Granted publication date: 20191217 Pledgee: Suzhou ronghua Leasing Co.,Ltd. Pledgor: SUZHOU LANXITE BIOTECHNOLOGY Co.,Ltd. Registration number: Y2020320010214 |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: No. 2-1, Dongwu South Road, Wuzhong District, Suzhou City, Jiangsu Province, 215000 Patentee after: SUZHOU PHARMACEUTICAL FACTORY, JIANGSU WUZHONG PHARMACEUTICAL Group Corp. Address before: 215123 Suzhou Industrial Park, Suzhou, Jiangsu, No. 388, Nanshui, 7 D, National Science and Technology Park, Nanshui University. Patentee before: SUZHOU LANXITE BIOTECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240327 Address after: No. 2-1, Dongwu South Road, Wuzhong District, Suzhou City, Jiangsu Province, 215000 Patentee after: JIANGSU WUZHONG PHARMACEUTICAL Group Corp. Country or region after: China Patentee after: SUZHOU PHARMACEUTICAL FACTORY, JIANGSU WUZHONG PHARMACEUTICAL Group Corp. Address before: No. 2-1, Dongwu South Road, Wuzhong District, Suzhou City, Jiangsu Province, 215000 Patentee before: SUZHOU PHARMACEUTICAL FACTORY, JIANGSU WUZHONG PHARMACEUTICAL Group Corp. Country or region before: China |